<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192280</url>
  </required_header>
  <id_info>
    <org_study_id>LHUB-001</org_study_id>
    <nct_id>NCT03192280</nct_id>
  </id_info>
  <brief_title>Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response</brief_title>
  <official_title>Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will test the feasibility of various imaging devices to detect local skin
      inflammation prior to clinical manifestation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Actual">July 6, 2017</completion_date>
  <primary_completion_date type="Actual">July 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-point of change from baseline and comparator in electro-magnetic spectra as measured by HSI PARC</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>Spectra from 400 - 1000 nm in 5 nm increments</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Skin Inflammation</condition>
  <arm_group>
    <arm_group_label>All study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.
Images of the treated area will be captured using multiple medical devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leukotriene B4</intervention_name>
    <description>Leukotriene B4 (LTB4)</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLIR One</intervention_name>
    <description>Thermal imaging attachment to iPhone</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SCIO</intervention_name>
    <description>Handheld near-IR molecular spectroscopy device</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MS Band 2</intervention_name>
    <description>Wearable &quot;watch-like&quot; device with multiple sensors</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AGE reader</intervention_name>
    <description>Portable bench top device for in-clinic near UV assessment</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HSI prototype (PARC) hyper-spectral camera</intervention_name>
    <description>Portable bench top device for in-clinic multispectral imaging</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iPhone 7</intervention_name>
    <description>Smart phone</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged &gt;25- &lt;40 years.

          -  Healthy, non-smoker.

          -  In the opinion of the investigator, the subject will be able to comply with the
             requirements of the protocol, including ability to present for all required visits.

          -  Subject is capable of understanding and signing an informed consent form.

          -  White origin (limit Skin Fitzpatrick I to III).

        Exclusion Criteria:

          -  Male aged &lt; 25 years or &gt;40 years.

          -  Female of any age.

          -  Tattoos on or within 5 cm of the area to be assessed.

          -  Scars on or with 5 cm of the area to be assessed.

          -  Current, active inflammatory skin disease, or past history of any inflammatory skin
             disease (other than acne) such as psoriasis, atopic dermatitis.

          -  Suffered from any significant allergies (i.e. food, environmental, contact).

          -  Subjects who are immunocompromised (i.e. HIV positive, Hepatitis C, transplant, etc.),
             based on clinical history.

          -  Subjects who currently have an activated immune system (e.g from current infection or
             recent vaccination).

          -  Subjects who have a history of chronic disease such as diabetes.

          -  Use of investigational therapy in the preceding month prior to screening visit.

          -  Use of G-CSF, GM-CSF, IL-2, IFNs, erythropoietin, systemic or inhaled steroids within
             one month of the screening visit.

          -  Use of oral analgesics/anti-inflammatories (e.g. paracetamol, ibuprofen, aspirin,
             codeine) or topical anti-inflammatories (e.g., ibuprofen) within 5 days of the
             screening visit.

          -  Concurrent disease or conditions that may present a risk to the subjects.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Griffin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Q-Pharm Pty Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Herston</city>
        <zip>QLD 4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

